NewAmsterdam Pharma Company N.V. Warrant financials
$11.40−0.78%
Close Sep 24, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7M | $3.0M | $32.0K | $348.0K | $19.1M | $3.0M | $12.8M | $29.1M | $2.3M | $1.4M | $803.0K | $2.9M |
| Gross profit | $3.7M | $3.0M | $32.0K | $348.0K | $19.1M | $3.0M | $12.8M | $29.1M | $2.3M | $1.4M | $803.0K | $2.9M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$64.9M | -$58.4M | -$66.0M | -$55.1M | -$35.6M | -$68.9M | -$43.2M | -$25.0M | -$52.6M | -$55.5M | -$51.1M | -$49.6M |
| Net income | -$64.1M | -$48.4M | -$74.9M | -$72.0M | -$17.4M | -$39.5M | -$92.2M | -$16.6M | -$39.0M | -$93.8M | -$49.5M | -$47.1M |
| Net margin | −1732.9% | −1593.5% | −234134.4% | −20691.1% | −90.7% | −1327.3% | −721.7% | −57.2% | −1711.6% | −6692.9% | −6163.8% | −1602.6% |
| Diluted EPS | $-0.52 | $-0.40 | $-0.62 | $-0.61 | $-0.15 | $-0.34 | $-0.93 | $-0.18 | $-0.41 | $-1.06 | $-0.60 | $-0.57 |
| EBITDA | -$64.8M | -$58.4M | -$65.9M | -$55.1M | -$35.6M | -$68.9M | -$43.2M | -$25.0M | -$52.6M | -$55.5M | -$51.1M | -$49.5M |
| Operating cash flow | -$39.2M | -$30.6M | -$40.9M | -$32.8M | -$37.7M | -$36.5M | -$37.5M | -$12.5M | -$54.0M | -$54.6M | -$33.1M | -$47.0M |
| Free cash flow | -$39.3M | -$30.6M | -$41.0M | -$32.8M | -$37.8M | -$36.5M | -$37.5M | -$12.6M | -$54.2M | -$55.0M | -$33.1M | -$47.0M |
| Diluted shares | 123.4M | 121.7M | 120.0M | 119.0M | 118.6M | 116.1M | 99.6M | 94.8M | 94.7M | 88.4M | 82.5M | 82.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $424.2M | $457.6M | $490.0M | $538.4M | $563.9M | $748.4M |
| Short-term investments | $209.7M | $178.5M | $146.2M | $164.5M | $175.3M | $60.1M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $704.5M | $732.6M | $769.3M | $786.4M | $815.1M | $818.4M |
| Total liabilities | $73.0M | $67.4M | $85.9M | $58.4M | $36.6M | $41.0M |
| Shareholders' equity | $631.4M | $665.2M | $683.4M | $728.1M | $778.5M | $777.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology